RxDoctor Payments Data

Gheath Al-Atrash, PhD

Medical Oncology · Houston, TXNPI 1518059898

Payments from drug & device makers

$291,738in general payments, 2019–2025

Across 10 payments — averaging $29,174 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$180K
  • Janssen Research & Development, LLC$107K
  • Novartis$5K
  • Bristol Myers Squibb$42

What the payments were for

  • Consulting fees$1,96598%
  • Food & beverage$422%

General payments by program year

21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck2$179,986
Janssen Research & Development, LLC2$106,624
Novartis5$5,086
Bristol Myers Squibb1$42

How this compares

$291,738 in reported general payments places this provider in the 60th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas

Medicare billing

Part B allowed, 2024
$39,939
Medicare patients
68
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ValacyclovirValacyclovir Hcl18$595

Paid to pharmacies, not to this prescriber.

Other medical oncology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →